Harmony Biosciences Holdings, Inc.
HRMYNext catalyst
Pitolisant GR
Narcolepsy (gastro-resistant formulation)
Get an email about HRMY's next catalysts
Track Harmony Biosciences Holdings (HRMY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (PDUFA date).See the timeline
3 upcoming, 1 past
FDA PDUFA Date HBS-102 (standard)
For narcolepsy. NDA filing. Extracted from SEC filing: 8-K
SourceHRMY Earnings Report
EPS Est: $1.00 | FQ end Sep/2026 | Call: bmo
Q3 2026 WAKIX net revenue of $269M with 400 net patient adds; positive preliminary MAD data for BP-205 showing favorable safety, tolerability and PK after 14 days of once-daily dosing; no liver or visual adverse events or clinically significant cardiovascular events; Pitolisant GR NDA under FDA review.
FDA PDUFA Date Pitolisant GR
For Narcolepsy (gastro-resistant formulation). NDA accepted in July 2026. Verified against the company SEC filing on 2026-10-16.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
No drugs found in this phase.
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
When is Harmony Biosciences Holdings, Inc.'s next FDA catalyst?→
Harmony Biosciences Holdings, Inc.'s (HRMY) next tracked catalyst is a PDUFA date expected Apr 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HRMY biotech catalysts?→
Add HRMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Harmony Biosciences Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
